Skip to main content

Table 3 Grade 3–4 immune related adverse events divided by study arm (N = 30 patients)

From: Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

 

Any Grade

Grade 3

Grade 4

Grade 3/4 Ipi 3 mg/kg

Grade 3/4 Ipi 10 mg/kg

No. Pts.

%

No. Pts.

%

No. Pts.

%

No. Pts.

%

No. Pts.

%

Adrenal insufficiency

10

33

2

7

0

0

0

0

2

7

Hypophysitis

2

7

2

7

0

0

0

0

2

7

Diarrhea/Colitis

15

50

3

10

0

0

2

7

1

3

AST/ALT

28

93

5

17

1

3

2

7

4

13

Lipase increased

9

30

3

10

0

0

0

0

3

10

Rash, maculo-papular

14

47

7

23

0

0

4

13

3

10

Pneumonitis

1

3

1

3

0

0

0

0

1

3

Autoimmune nephritis

1

3

1

3

0

0

0

0

1

3